Tumour suppressors: The trials of separation

p832 | doi:10.1038/nrc1480

Early detection: Making an early mark?

p833 | doi:10.1038/nrc1482

Drug resistance: Sidelined

p834 | doi:10.1038/nrc1481

Mouse models: Inducing dormancy

p834 | doi:10.1038/nrc1485

Tumorigenesis: Divining forks for developing tumours

p835 | doi:10.1038/nrc1489

Genetics: Gains and losses

p836 | doi:10.1038/nrc1483

Fertility: Against the odds

p836 | doi:10.1038/nrc1484

Tumorigenesis: Survivin death

p837 | doi:10.1038/nrc1486

Ovarian cancer: Controlled aggression

p838 | doi:10.1038/nrc1487

Friends or foes — bipolar effects of the tumour stroma in cancer

Margareta M. Mueller & Norbert E. Fusenig

p839 | doi:10.1038/nrc1477

• Abstract
• Full Text
• PDF (368 KB)

Association studies for finding cancer-susceptibility genetic variants

Paul D. P. Pharoah, Alison M. Dunning, Bruce A. J. Ponder & Douglas F. Easton

p850 | doi:10.1038/nrc1476

• Abstract
• Full Text
• PDF (192 KB)

Antitumour effects of antiretroviral therapy

Paolo Monini, Cecilia Sgadari, Elena Toschi, Giovanni Barillari & Barbara Ensoli

p861 | doi:10.1038/nrc1479

• Abstract
• Full Text
• PDF (427 KB)

The emerging roles of human tissue kallikreins in cancer

Carla A. Borgoño & Eleftherios P. Diamandis

p876 | doi:10.1038/nrc1474

• Abstract
• Full Text
• PDF (321 KB)

View Correspondence (May 2005; May 2005) associated with this article.

Why do cancers have high aerobic glycolysis?

Robert A. Gatenby & Robert J. Gillies

p891 | doi:10.1038/nrc1478

• Abstract
• Full Text
• PDF (519 KB)